The relationship of serum vitamin A, cholesterol, and triglycerides to the incidence of ovarian cancer

Das, N.P.; Ma, Charlie; Salmon, Y M

doi:10.1016/0885-4505(87)90029-6

Cited by 15 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although contradictory results have been found in prospective studies (39,40), our data support the notion that vitamin A and its derivatives play a key role in ovarian carcinogenesis (10) and provide further rationale for assessing their effect in prospective studies.…”

Section: Discussionsupporting

confidence: 79%

A Phase I-II Preoperative Biomarker Trial of Fenretinide in Ascitic Ovarian Cancer

Colombo

Formelli²,

Cantù

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Purpose: To evaluate study feasibility, toxicity, drug concentrations, and activity of escalating doses of the synthetic retinoid fenretinide [N-(4-hydroxyphenyl)retinamide (4-HPR)] in ovarian cancer by measuring serum CA125 and cytomorphometric biomarkers in cancer cells collected from ascitic fluid before and after treatment. Methods: Twenty-two naive patients with ascitic ovarian cancer were treated with escalating doses of 4-HPR at 0, 400, 600, and 800 mg/d for 1 to 4 weeks before surgery. Changes in the proportion of proliferating cells expressed by Ki67 and computer-assisted cytomorphometric variables (nuclear area, DNA index, and chromatin texture) were determined in ascitic cells. Drug levels were measured by high-performance liquid chromatography. Results: Doses up to 800 mg/d were well tolerated, and no adverse reactions occurred. There was no effect of 4-HPR on changes in serum CA125, Ki67 expression, which were assessed in 75% of subjects, and cytomorphometric variables, which were assessed in 80% of subjects. Plasma retinol levels were significantly lower in affected women than healthy donors. 4-HPR plasma concentrations increased slightly with increasing doses and attained a 1.4 Mmol/L concentration with 800 mg/d. Drug levels in malignant ascitic cells and tumor tissue were higher than in plasma but were 50 and 5 times lower, respectively, than in carcinoma cells treated in vitro with 1 Mmol/L 4-HPR. Conclusions: Cell biomarkers can be measured in ascitic cells to assess drug activity. Under our experimental conditions, 4-HPR did not show activity in advanced ovarian cancer cells. However, clinical evidence supports further investigation of fenretinide for ovarian cancer prevention. (Cancer Epidemiol Biomarkers Prev 2006;15(10):1914 -9)

show abstract

Section: Discussionsupporting

confidence: 79%

A Phase I-II Preoperative Biomarker Trial of Fenretinide in Ascitic Ovarian Cancer

Colombo

Formelli²,

Cantù

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Variations in the normal lipid metabolism-particularly of serum triglycerideshave been observed in breast cancer and ovarian cancer patients. Two studies that illustrate examples of such results are those by Das and colleagues and Capasso and colleagues (2,3), both of which present evidence for a positive association between triglycerides and the risk of developing these cancers. It has been suggested for both breast cancer and ovarian cancer that low levels of HDL (high-density lipoprotein; a common comorbidity of obesity) could be reflective of an unfavorable hormonal profile which, in turn, would increase the risk (4,5).…”

Section: Introductionmentioning

confidence: 92%

Lipid Profiles and Risk of Breast and Ovarian Cancer in the Swedish AMORIS Study

Melvin

Seth

Holmberg

et al. 2012

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Obesity is a risk factor for breast and ovarian cancer; the mechanisms of action are not completely understood. Perturbed lipid metabolism often accompanies obesity; we therefore ascertained the associations between lipid components and breast and ovarian cancer risk in a prospective cohort study.Methods: A total of 234,494 women with baseline measurements of triglycerides and total cholesterol and glucose were selected from the AMORIS database.A total of 27,394 had measurements of high-density lipoprotein, low-density lipoprotein, apolipoprotein (Apo) B, and A-I. Associations between quartiles and dichotomized values of lipid components and breast and ovarian cancer risk were analyzed using Cox proportional hazard models.Results: We identified 6,105 women diagnosed with breast cancer and 808 women diagnosed with ovarian cancer. A weak trend was observed between triglycerides and breast cancer (HR, 1.01, 95% Confidence Interval, 0.94-1.09; 0.93 (0.86-1.00) 0.91 (0.84-0.99), second, third, and fourth quartiles; P ¼ 0.01). No other associations between lipid components and risk of breast cancer or ovarian cancer showed statistical significance.Conclusions: A weak protective association was found between levels of triglycerides and risk of breast cancer.Impact: An analysis including information on tumour characteristics of ovarian cancer and breast cancer may provide more insight in possible links between lipid metabolism and the risk of these cancers. Cancer Epidemiol Biomarkers Prev; 21(8);

show abstract

“…Of the 1619 records obtained from the primary literature search, 377 duplicates and 1079 records were excluded after examining titles and abstracts. Also, 151 records were excluded after full-text evaluation and 12 studies [6][7][8][9][10][16][17][18][19][20][21][22] comprising 1767 OT cases and 229,167 non-cases of OT met the inclusion criteria ( Fig. 1).…”

Section: Literature Searchmentioning

confidence: 99%

“…Overall pooled mean estimates differed insignificantly upon the exclusion of a single study at a time (Table S2), but few studies [7,17,18,21,22] exerted negligible influence on the overall pooled mean estimates of the meta-analysis.…”

Section: Sensitivity Analysismentioning

confidence: 99%

Lipid profile and risk of ovarian tumours: a meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background: Existing data from several reports on the association between lipid profile and ovarian tumour (OT) suggests divergent conclusions. Our aim was to examine whether circulating lipid profile: total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) differed between cases and noncases of OT. Methods: Electronic repositories; PUBMED, EMBASE and Cochrane library were explored through December 2019 to retrieve published articles for inclusion in the meta-analysis after quality assessment. Heterogeneity was assessed using I 2 statistics, the effect of individual studies on the overall effect size was tested using sensitivity analysis and funnel plot was used to evaluate publication bias. Results: Twelve studies, involving 1767 OT cases and 229,167 non-cases of OT were included in this meta-analysis and I 2 statistics ranged between 97 and 99%. Mean circulating TC (− 16.60 [− 32.43, − 0.77]mg/dL; P = 0.04) and HDL (− 0.25[− 0.43, − 0.08]mmol/L; P = 0.005) were significantly lower among OT cases compared to non-OT cases. Conclusion: Decreased TC and HDL profiles were observed among subjects with OT in this collection of reports. The implications of TC and HDL in tumour manifestations and growth need to be validated in a large multi-ethnic longitudinal cohort adjusting for relevant confounders.

show abstract

The relationship of serum vitamin A, cholesterol, and triglycerides to the incidence of ovarian cancer

Cited by 15 publications

References 23 publications

A Phase I-II Preoperative Biomarker Trial of Fenretinide in Ascitic Ovarian Cancer

A Phase I-II Preoperative Biomarker Trial of Fenretinide in Ascitic Ovarian Cancer

Lipid Profiles and Risk of Breast and Ovarian Cancer in the Swedish AMORIS Study

Lipid profile and risk of ovarian tumours: a meta-analysis

Contact Info

Product

Resources

About